This Editorial discusses the US Preventive Services Task Force recommendations statement on screening for lipid disorders in children and adolescents and the low value this screening has.
This population-based cohort study evaluates trends in the prescription and cost of generic atorvastatin among patients with commercial insurance coverage.
This study assesses the relationship between low-density lipoprotein cholesterol levels achieved with statin treatment and cardiovascular events in patients with preexisting ischemic heart disease.
This study explores whether receipt of pharmaceutical industry-sponsored meals by physicians is associated with their prescribing the promoted brand-name drug at higher rates to Medicare beneficiaries.
This secondary analysis of a randomized clinical trial assesses the effect of pharmacologic therapy and clinical risk factors on incident conduction system disease in patients with hypertension.
This study uses Medicare Part D prescriptions claims data and Massachusetts physicians payment database data to evaluate associations between industry payments to physicians and prescribing of brand-name statins.
This cross-sectional study estimates potential savings through therapeutic substitution in terms of both overall and out-of-pocket expenditures of branded drugs when a generic in the same class with the same indication was available.
In a nationally representative sample of older adults, this study characterizes changes in the prevalence of medication use and quantifies the frequency and types of potential major drug-drug interactions.
This Special Communication identifies and highlights articles published in 2014 that are most likely to influence medical overuse, organized into the categories of overdiagnosis, overtreatment, and methods to avoid overuse.
This survey investigates the use of statins in individuals older than 79 years by vascular disease.
This cohort study uses The Health Improvement Network data to assess whether statin users show acute decline in memory compared with nonusers and compared with users of nonstatin lipid-lowering drugs.
This pragmatic trial suggests that stopping statin medication therapy is safe and may be associated with benefits, including improved quality of life, use of fewer nonstatin medications, and a corresponding reduction in medication costs. See the Invited Commentary by Holmes and Todd.
This randomized clinical trial found that among men and women with elevated high-sensitivity C-reactive protein levels enrolled in a large trial of rosuvastatin therapy for cardiovascular disease, statin therapy did not reduce the risk of fracture.
The Women’s Health Study is a nationwide cohort of US women free of cardiovascular disease, cancer, or other major illness at baseline from 1992 to 1995. A total of 27 542 women aged 45 to 79 years with complete ascertainment of plasma lipids and other risk factors were followed for a median of 10 years.